General-practitioner-led alcohol and other drugs withdrawal: Supporting patient choice, safety and success.

BACKGROUND: Alcohol or other drug (AOD) withdrawal is a common reason for patients to seek treatment. Ambulatory, or 'home-based', AOD withdrawal for patients who are low risk is a useful intervention for general practitioners (GPs) to help empower their patients to improve their health and make meaningful change to their AOD use. OBJECTIVE: This article explores the themes of patient choice, safety and optimising success in GP-led withdrawal. The four-step framework of 'who', 'prepare', 'withdrawal' and 'follow-up' outlines how to best support patients in the general practice setting to undertake a withdrawal. DISCUSSION: There are many benefits to a GP-led, home-based AOD withdrawal. The strategies to facilitate choice and safety and to optimise withdrawal success described in the article include careful patient selection, preparing the patient using domains of whole-person care, clarifying the patient's goals and stage of change, support during withdrawal and fostering long-term treatment in general practice.

Engaging patients who use alcohol and other drugs: A practical approach.

BACKGROUND: The treatment of alcohol and other drugs (AOD)-related issues is an essential skill for all general practitioners (GPs). The ongoing harm and significant burden of disease experienced by people who use AOD, as well as the impact of this on their families and communities, displays the need for engagement and upskilling in this clinical area. OBJECTIVE: Provide GPs with a clear and practical approach to supporting patients who use AOD. DISCUSSION: Historically, AOD use has been associated with shame, societal judgement and a punitive treatment approach. These factors have been shown to adversely affect treatment outcomes, including a significant delay to, and low engagement with, treatment. An approach focusing on rapport and the therapeutic alliance is best practice and incorporates a strengths-based approach of whole-person, trauma-informed care and motivational interviewing to support behaviour change.

Impact of Australian general practice alcohol and other drugs education: a qualitative evaluation.

BACKGROUND: Many GPs are challenged to deliver safe and effective care for patients who use alcohol and other drugs (AOD). The Royal Australian College of General Practitioners (RACGP) developed the AOD GP Education Programme to support Australian GPs and optimise AOD care in the community. How the programme impacted GP participants is not yet fully understood. AIM: To explore the views and experiences of GP participants who completed the AOD GP Education Programme, and AOD experts who were involved in the programme as a presenter or mentor. DESIGN & SETTING: Situated in the constructivist paradigm, this qualitive descriptive study engaged GPs across Australia. METHOD: This study employed semi-structured, online, focus groups interviews. Data were analysed thematically. RESULTS: Five focus groups were held with a total of 35 GP participants. Five themes developed, which illustrated that the study participants viewed the programme design as comprehensive and flexible. It has also been shown that participants' individual learning needs were addressed. Impacts of the programme on clinical practice included the following: confidence to care for patients who use AOD; confidence to collaborate with colleagues in delivery of AOD care; confidence to develop AOD professional networks in their community setting; and confidence to manage complex AOD presentations. CONCLUSION: Participants described the AOD programme as a high quality and positive educational experience. The prioritisation of core treatment skills (whole-person care and structured approaches to behavioural change) was a feature of the professional development programme. The AOD programme design is a practical model to implement for future AOD GP education and continuing professional development.

Protocol for a single patient therapy plan: A randomised, double-blind, placebo-controlled N-of-1 trial to assess the efficacy of cannabidiol in patients with intractable epilepsy.

AIM: This paper describes the use of the single patient therapy plan (SPTP). The SPTP has been designed to assess the efficacy at an individual level of a commercially available cannabinoid product, cannabidiol, in reducing seizure frequency in paediatric patients with intractable epilepsy. METHODS: The SPTP is a randomised, double-blind, placebo-controlled N-of-1 trial designed to assess the efficacy of treatment in a neurology outpatient setting. The primary objective of the SPTP is to assess the efficacy of cannabidiol in reducing seizure frequency in each patient with intractable epilepsy, with change in seizure frequency being the primary outcome of interest. The analysis adopts a Bayesian approach, which provides results in the form of posterior probabilities that various levels of benefit (based on the primary outcome measure, seizure frequency) have been achieved under active treatment compared to placebo, accompanied by decision rules that provide thresholds for deciding whether treatment has been successful in the individual patient. The SPTP arrangement is most accurately considered part of clinical practice rather than research, since it is aimed at making clinical treatment decisions for individual patients and is not testing a hypothesis or collecting aggregate data. Therefore, Human Research Ethics Committee approval was considered not to be required, although it is recommended that hospital Clinical Ethics Committees provide ethical oversight. CONCLUSION: These SPTP resources are made available so that they may inform clinical practice in the treatment of severe epilepsy or adapted for use in other conditions.

A review of the public health management of shigellosis in Australia in the era of culture-independent diagnostic testing.

OBJECTIVE: To review the national case definition for shigellosis following the introduction of culture independent diagnostic testing by clinical laboratories and provide evidence to reform jurisdictional public health practices for the management shigellosis., . METHODS: A review of all Australian jurisdictional public health guidelines for shigellosis was conducted. Victorian 2014 shigellosis data were analysed: demographics and risk factors for cases identified by conventional culture or culture-independent diagnostic methods were described. RESULTS: There was considerable variation in reporting of cases to the National Notifiable Disease Surveillance System (NNDSS) by the eight Australian jurisdictions, with an array of classifications based on diagnostic testing methodologies. Analysis of Victorian 2014 shigellosis data found that culture positive cases were more likely to have reported men who have sex with men (MSM) as a risk factor than PCR positive only cases (p<0.0001) and less likely to have reported overseas travel during their incubation period (p<0.0001). Over a 10-year period (2005 to 2014), only two of 86 cases who were employed in high-risk occupations had ongoing positive faecal cultures after appropriate treatment. CONCLUSIONS: The national surveillance case definition for shigellosis should be reviewed to facilitate standardised reporting across Australia. All jurisdictions must consider the public health significance of PCR positive only results in their surveillance risk assessments to inform management of shigellosis cases.